Off-Label Promotion Cases Need Better Oversight In Justice Dept., WLF Says
Executive Summary
Responsibility for coordination of federal off-label promotion investigations should be transferred to the Department of Justice Criminal Division to help ensure appropriate protection of First Amendment rights, the Washington Legal Foundation said in a recent petition to DoJ
You may also be interested in...
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Good Reprint Practices: FDA’s Draft Guidance Aims For Middle Ground
A newly released FDA draft guidance detailing a roadmap for acceptable dissemination of information on off-label drug use implies that companies need to garner enough data for a new drug application before distributing content
Pharma Should Enlist Patients, Physicians To Fight Off-Label Litigation
Drug makers should partner with patient advocacy groups and physicians to fight a growing pattern of litigation related to the dissemination of off-label drug information, Sidley Austin Brown & Wood Partner Paul Kalb said during a Drug Information Association workshop Feb. 22 in New York